Global Artificial Pancreas Medical Devices Landscape Report 2021: Pipeline Products, Products Under Development, Companies and Product Overview, Recent Developments - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Artificial Pancreas - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

"Artificial Pancreas Medical Devices Pipeline Product Landscape, 2021" provides comprehensive information about the Artificial Pancreas pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Artificial Pancreas helps people with diabetes, primarily type 1, automatically and continuously control their blood glucose level by providing the substitute endocrine functionality of a healthy pancreas.

Scope

• Extensive coverage of the Artificial Pancreas under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment/industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Artificial Pancreas under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Artificial Pancreas Overview

3 Products under Development

3.1 Artificial Pancreas - Pipeline Products by Stage of Development

3.2 Artificial Pancreas - Pipeline Products by Territory

3.3 Artificial Pancreas - Pipeline Products by Regulatory Path

3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date

3.5 Artificial Pancreas - Ongoing Clinical Trials

4 Artificial Pancreas - Pipeline Products under Development by Companies

4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development

4.2 Artificial Pancreas - Pipeline Products by Stage of Development

5 Artificial Pancreas Companies and Product Overview

5.1 Admetsys Corp

5.2 Advanced Biosensors-Ohio LLC

5.3 Beta Bionics Inc

5.4 Beta-O2 Technologies Ltd

5.5 Bigfoot Biomedical Inc

5.6 BioTex Inc

5.7 Cerco Medical LLC

5.8 Converge Biotech, Inc.

5.9 Covalor Medical, LLC

5.10 De Montfort University

5.11 Debiotech SA

5.12 Defymed SAS

5.13 Diabeloop SA

5.14 EOFlow Co Ltd

5.15 Giner Inc

5.16 Harvard John A Paulson School of Engineering and Applied Sciences

5.17 Healios Inc

5.18 Humacyte Inc

5.19 Ideal Medical Technologies Inc

5.20 Imperial College London

5.21 Inreda Diabetic BV

5.22 Insulet Corp

5.23 Joslin Diabetes Center

5.24 Kencak LLC

5.25 McGill University

5.26 Medtronic Diabetes

5.27 Medtronic Inc

5.28 Miromatrix Medical Inc

5.29 Pacific Diabetes Technologies, Inc.

5.30 Pancreum, LLC

5.31 PharmaCyte Biotech Inc

5.32 Polytechnic University of Valencia

5.33 Rensselaer Polytechnic Institute

5.34 Senseonics Holdings Inc

5.35 Stanford University

5.36 TecMed Inc

5.37 The Alfred Mann Foundation

5.38 TypeZero Technologies LLC

5.39 U-Needle BV

5.40 Universidad Autonoma de Madrid

5.41 University of California San Francisco

5.42 University of California Santa Barbara

5.43 University of Cambridge

5.44 University of Florida

5.45 University of Minnesota

5.46 University of Newcastle

5.47 WaveForm Technologies Inc

5.48 XERIS Pharmaceuticals Inc

5.49 Yale University

6 Artificial Pancreas - Recent Developments

6.1 May 06, 2021: Insulet Reports First Quarter 2021 Revenue Increase of 27% Year-Over-Year

6.2 May 05, 2021: University of Cambridge appoints Dr Diarmuid O'Brien as new Chief Executive of Cambridge Enterprise

6.3 Apr 05, 2021: Insulet to Announce First Quarter 2021 Financial Results on May 6, 2021

6.4 Mar 02, 2021: Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on March 9, 2021

6.5 Feb 16, 2021: Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2021

6.6 Nov 09, 2020: Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

6.7 Aug 06, 2020: Insulet to Announce Second Quarter 2020 Financial Results on August 6, 2020

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/294ugj